AFELETECAN HYDROCHLORIDE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C45H49N7O11S.ClH
Molecular Weight	932.437
Optical Activity	UNSPECIFIED
Defined Stereocenters	8 / 8
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cl.CC[C@@]4(OC(=O)[C@@H](NC(=O)[C@H](CC1=CNC=N1)NC(=S)NC2=CC=C(O[C@H]3O[C@@H](C)[C@@H](O)[C@@H](OC)[C@@H]3O)C=C2)C(C)C)C(=O)OCC5=C4C=C6N(CC7=CC8=CC=CC=C8N=C67)C5=O

InChI

InChIKey=XQWYWSHYKUJQDC-NZGUGFNHSA-N

InChI=1S/C45H49N7O11S.ClH/c1-6-45(30-17-33-35-25(15-24-9-7-8-10-31(24)49-35)19-52(33)40(56)29(30)20-60-43(45)58)63-41(57)34(22(2)3)51-39(55)32(16-27-18-46-21-47-27)50-44(64)48-26-11-13-28(14-12-26)62-42-37(54)38(59-5)36(53)23(4)61-42;/h7-15,17-18,21-23,32,34,36-38,42,53-54H,6,16,19-20H2,1-5H3,(H,46,47)(H,51,55)(H2,48,50,64);1H/t23-,32-,34-,36+,37-,38+,42+,45-;/m0./s1

HIDE SMILES / InChI

Molecular Formula	C45H49N7O11S
Molecular Weight	895.976
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	8 / 8
E/Z Centers	0
Optical Activity	UNSPECIFIED

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://adisinsight.springer.com/drugs/800013469 | https://www.ncbi.nlm.nih.gov/pubmed/16133797

Afeletecan (Bay 38-3441) is a camptothecin glycoconjugate which stabilizes the active lactone form of camptothecin and allows selective uptake into tumor cells. Afeletecan is a topoisomerase inhibitor. Afeletecan was in phase I clinical trials with Bayer for the treatment of cancer; however, development appears to have been discontinued.

Originator

Approval Year

PubMed

Title	Date	PubMed
Gateways to clinical trials. March 2003.	2003 Mar	12731460

Patents

Sample Use Guides

In Vivo Use Guide

Solid tumors: A total of 81 patients with advanced solid tumors were treated with BAY 38-3441 either at doses of 20, 40, 67, 100, 140, 210, 315, 470 and 600 mg/m2/day for 1 day every 3 weeks (single-dose schedule), or at doses of 126, 189, 246, 320 and 416 mg/m2/day once daily for three consecutive days every 3 weeks (3-day schedule). 3-day schedule for BAY 38-3441 at a dose of 320 mg/m2/day as 30-min infusions for further phase II studies was recommended.

Route of Administration: Intravenous

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:41:32 GMT 2023` Edited by `admin` on `Fri Dec 15 15:41:32 GMT 2023`
Record UNII	DTJ7VPW43J
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

AFELETECAN HYDROCHLORIDE

Common Name

English

BAY 56-3722

Code

English

BAY56-3722

Code

English

L-VALINE, N-(((4-((6-DEOXY-3-O-METHYL-.BETA.-L-GALACTOPYRANOSYL)OXY)PHENYL)AMINO)THIOXOMETHYL)-L-HISTIDYL-, (4S)-4-ETHYL-3,4,12,14-TETRAHYDRO-3,14-DIOXO-1H-PYRANO(3',4':6,7)INDOLIZINO(1,2-B)QUINOLIN-4-YL ESTER, HYDROCHLORIDE (1:1)

Common Name

English

L-VALINE, N-(((4-((6-DEOXY-3-O-METHYL-.BETA.-L-GALACTOPYRANOSYL)OXY)PHENYL)AMINO)THIOXOMETHYL)-L-HISTIDYL-, (4S)-4-ETHYL-3,4,12,14-TETRAHYDRO-3,14-DIOXO-1H-PYRANO(3',4':6,7)INDOLIZINO(1,2-B)QUINOLIN-4-YL ESTER, MONOHYDROCHLORIDE

Common Name

English

BAY-563722

Code

English

BAY 38-3441

Brand Name

English

Afeletecan hydrochloride [WHO-DD]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C2843